Persistence of the neutralizing antibody response after SARS-CoV-2 infection

被引:7
|
作者
Shim, Sang-Mu [1 ]
Kim, Jun-Won [2 ]
Jung, Sunhee [2 ]
Jung, Yujung [2 ]
Woo, Hye-Min [2 ]
Yang, Jeong-Sun [2 ]
Kim, Kyung-Chang [2 ]
Lee, Joo-Yeon [3 ]
机构
[1] Korea Dis Control & Prevent Agcy, Korea Natl Inst Hlth, Div Acute Virus Dis, Cheongju, South Korea
[2] Korea Dis Control & Prevent Agcy, Div Emerging Virus & Vector Res, Korea Natl Inst Hlth, Cheongju, South Korea
[3] Korea Dis Control & Prevent Agcy, Korea Natl Inst Hlth, Ctr Emerging Virus Res, 187 Osongsaengmyeong2-ro, Cheongju 28159, Chungcheongbuk, South Korea
关键词
COVID-19; ELISA; Neutralizing antibody; Plaque-reduction neutralizing test; SARS-CoV-2;
D O I
10.1016/j.cmi.2021.12.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: Neutralizing antibodies are among the factors used to measure an individual's immune status for the control of infectious diseases. We aimed to confirm the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody levels in patients who had recovered from coronavirus disease 2019 (COVID-19). Methods: Plasma donors in South Korea who had completely recovered from SARS-CoV-2 infection had follow-up testing to determine the persistence of neutralizing antibodies using a plaque-reduction neutralization test and ELISA. Results: Of the 111 participants-aged 20-29 years, 37/111 (33.3%); 30-39 years, 17/111 (15.3%); 40 -49 years, 23/111 (20.7%); 50-59 years, 21/111 (18.9%); 60-65 years, 13/111 (11.7%); male, 43/111 (38.7%); female, 68/111 (61.3%)-66.1% still had neutralizing antibodies approximately 9 months (range 255-302 days) after confirmation of the diagnosis. Conclusions: In this study we analysed the titre of neutralizing antibodies associated with predicting immune status in individuals with natural infection. Information about the persistence and change in levels of neutralizing antibodies against SARS-CoV-2 can be utilized to provide evidence for developing vaccination schedules for individuals with previous infection. (C) 2022 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
引用
收藏
页码:614.e1 / 614.e4
页数:4
相关论文
共 50 条
  • [41] SARS-CoV-2 neutralising antibody response to bivalent booster after omicron infection
    Springer, David N.
    Medits, Iris
    Weseslindtner, Lukas
    Stiasny, Karin
    Aberle, Judith H.
    LANCET MICROBE, 2024, 5 (01): : E8 - E8
  • [42] Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection
    Wang, Hao
    Yuan, Yu
    Xiao, Mingzhong
    Chen, Li
    Zhao, Youyun
    Zhang, Haiwei
    Long, Pinpin
    Zhou, Yana
    Xu, Xi
    Lei, Yanshou
    Wu, Bihao
    Diao, Tingyue
    Cai, Hao
    Liu, Li
    Shao, Zuoyu
    Wang, Jingzhi
    Bai, Yansen
    Wang, Kai
    Peng, Miao
    Liu, Linlin
    Han, Shi
    Mei, Fanghua
    Cai, Kun
    Lei, Yake
    Pan, An
    Wang, Chaolong
    Gong, Rui
    Li, Xiaodong
    Wu, Tangchun
    CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (07) : 1832 - 1834
  • [43] Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection
    Hao Wang
    Yu Yuan
    Mingzhong Xiao
    Li Chen
    Youyun Zhao
    Pinpin Haiwei Zhang
    Yana Long
    Xi Zhou
    Yanshou Xu
    Tingyue Lei
    Hao Bihao Wu
    Li Diao
    Zuoyu Cai
    Jingzhi Liu
    Yansen Shao
    Kai Wang
    Miao Bai
    Linlin Wang
    Shi Peng
    Fanghua Liu
    Kun Han
    Yake Mei
    An Cai
    Chaolong Lei
    Rui Pan
    Xiaodong Wang
    Tangchun Gong
    Cellular & Molecular Immunology, 2021, 18 : 1832 - 1834
  • [44] IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis
    De Vriese, An S.
    Reynders, Marijke
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 76 (03) : 440 - 441
  • [45] Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
    Callegaro, Annapaola
    Borleri, Daniela
    Farina, Claudio
    Napolitano, Gavino
    Valenti, Daniela
    Rizzi, Marco
    Maggiolo, Franco
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (07) : 4612 - 4615
  • [46] Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges
    Tangchun Wu
    Frontiers of Medicine, 2020, 14 : 816 - 819
  • [47] Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges
    Wu, Tangchun
    FRONTIERS OF MEDICINE, 2020, 14 (06) : 816 - 819
  • [48] Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection
    Linderman, Susanne L.
    Lai, Lilin
    Gamarra, Estefany L. Bocangel
    Lau, Max S. Y.
    Edupuganti, Srilatha
    Surie, Diya
    Tenforde, Mark W.
    Chappell, James D.
    Mohr, Nicholas M.
    Gibbs, Kevin W.
    Steingrub, Jay S.
    Exline, Matthew C.
    Shapiro, Nathan I.
    Frosch, Anne E.
    Qadir, Nida
    Davis-Gardner, Meredith E.
    McElrath, M. Juliana
    Lauring, Adam S.
    Suthar, Mehul S.
    Patel, Manish M.
    Self, Wesley H.
    Ahmed, Rafi
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (23):
  • [49] Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
    Gloeckner, Stefan
    Hornung, Franziska
    Baier, Michael
    Weis, Sebastian
    Pletz, Mathias W.
    Deinhardt-Emmer, Stefanie
    Loffler, Bettina
    VIRUSES-BASEL, 2021, 13 (10):
  • [50] Persistence of IgG response to SARS-CoV-2
    Duysburgh, Els
    Mortgat, Laure
    Barbezange, Cyril
    Dierick, Katelijne
    Fischer, Natalie
    Heyndrickx, Leo
    Hutse, Veronik
    Thomas, Isabelle
    Gucht, Steven Van
    Vuylsteke, Bea
    Arien, Kevin K.
    Desombere, Isabelle
    LANCET INFECTIOUS DISEASES, 2021, 21 (02): : 163 - 164